The role and mechanism of IL‑35 in myasthenia gravis (Review)

Fecto F: Myasthenia gravis: Mechanisms, clinical syndromes, and diagnosis. Dis Mon. 71:1019692025. View Article : Google Scholar

Harish Bindignavile S: Myasthenia Gravis-an updated review. Int Ophthalmol Clin. 66:55–61. 2026. View Article : Google Scholar

Jacobson MH, Makadia R, Anderson AEL, Choudhry Z, Hall N, Hardin J, Huang S, Massey JM, Ostropolets A, Sun R, et al: Characterizing perinatal treatment patterns and outcomes in myasthenia gravis. Muscle Nerve. 73:269–276. 2026. View Article : Google Scholar :

Suzuki S: Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis. Immunol Med. 48:117–123. 2025. View Article : Google Scholar : PubMed/NCBI

Oh S, Khani-Habibabadi F, O'Connor KC and Payne AS: Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Sci Adv. 11:eadt07952025. View Article : Google Scholar : PubMed/NCBI

Golabi M, Yousefi Z, Jafarinia M, Montazeri M, Bastan S, Ghezelbash B and Eskandari N: miRNAs as the important regulators of myasthenia gravis: Involvement of major cytokines and immune cells. Immunol Res. 71:153–163. 2023. View Article : Google Scholar

McGettigan SE and Debes GF: Immunoregulation by antibody secreting cells in inflammation, infection, and cancer. Immunol Rev. 303:103–118. 2021. View Article : Google Scholar : PubMed/NCBI

Yasuda M, Uzawa A, Ozawa Y, Kojima Y, Onishi Y, Akamine H and Kuwabara S: Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies. J Neuroimmunol. 384:5782052023. View Article : Google Scholar : PubMed/NCBI

Martinez Salazar A, Mokhtari S, Peguero E and Jaffer M: The role of complement in the pathogenesis and treatment of myasthenia gravis. Cells. 14:7392025. View Article : Google Scholar : PubMed/NCBI

Moniz Dionísio J, Ambrose P, Burke G, Farrugia ME, Garcia-Reitboeck P, Hewamadduma C, Hill M, Howard RS, Jacob S, Kullmann D, et al: Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience. J Neurol Neurosurg Psychiatry. 96:322–328. 2025. View Article : Google Scholar : PubMed/NCBI

Reyes-Leiva D, Carbayo Á, Vesperinas-Castro A, Rojas-García R, Querol L, Turon-Sans J, Pla-Junca F, Olivé M, Gallardo E, Pujades-Rodriguez M and Cortés-Vicente E: Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis. Eur J Neurol. 32:e164632025. View Article : Google Scholar

Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, Hoffmann S, Hoffmann HS, Jander S, Keller C, et al: Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 16:175628642312132402023. View Article : Google Scholar : PubMed/NCBI

Goleij P, Amini A, Sanaye PM, Heidari MM, Tabari MAK, Aschner M, Larsen DS, Khan H and Daglia M: The IL-12 family cytokines in neurodegenerative diseases: Dual roles in neurotoxicity and neuroprotection. Inflammopharmacology. 33:5235–5256. 2025. View Article : Google Scholar : PubMed/NCBI

Wei X, Zhang J, Cui J, Xu W, Zhao G, Guo C, Yuan W, Zhou X and Ma J: Adaptive plasticity of natural interleukin-35-induced regulatory T cells (Tr35) that are required for T-cell immune regulation. Theranostics. 14:2897–2914. 2024. View Article : Google Scholar : PubMed/NCBI

Choi JK, Mbanefo EC, Yadav MK, Alhakeem SA, Nagarajan V, Nunes NS, Kanakry CG and Egwuagu CE: Interleukin 35-producing B cells prolong the survival of GVHD mice by secreting exosomes with membrane-bound IL-35 and upregulating PD-1/LAG-3 checkpoint proteins. Theranostics. 15:3610–3626. 2025. View Article : Google Scholar : PubMed/NCBI

Wang H and Zhang H: The role of IL-12 family cytokines in the pathogenesis of periodontal disease: A therapeutic approach. Immunol Invest. 21:1–39. 2025.

Huang Q, Wang Y, Si C, Zhao D, Wang Y and Duan Y: Interleukin-35 modulates the imbalance between regulatory T cells and T helper 17 cells in enterovirus 71-induced hand, foot, and mouth disease. J Interferon Cytokine Res. 37:522–530. 2017. View Article : Google Scholar : PubMed/NCBI

Xie M, Zhu Y, Zhou Y, Wang Q, Gu E, Chu Y and Wang L: Interleukin-35-producing B cells rescues inflammatory bowel disease in a mouse model via STAT3 phosphorylation and intestinal microbiota modification. Cell Death Discov. 9:672023. View Article : Google Scholar

Wu D, Wang L, Hong D, Zheng C, Zeng Y, Ma H, Lin J, Chen J and Zheng R: Interleukin 35 contributes to immunosuppression by regulating inflammatory cytokines and T cell populations in the acute phase of sepsis. Clin Immunol. 235:1089152022. View Article : Google Scholar : PubMed/NCBI

Tao P, Su B, Mao X, Lin Y, Zheng L, Zou X, Yang H, Liu J and Li H: Interleukin-35 inhibits NETs to ameliorate Th17/Treg immune imbalance during the exacerbation of cigarette smoke exposed-asthma via gp130/STAT3/ferroptosis axis. Redox Biol. 82:1035942025. View Article : Google Scholar : PubMed/NCBI

Wang D and Liu R: The IL-12 family of cytokines: Pathogenetic role in diabetic retinopathy and therapeutic approaches to correction. Naunyn Schmiedebergs Arch Pharmacol. 398:125–133. 2025. View Article : Google Scholar

Slawek A, Kubik P, Psurski M, Kedzierska AE and Chelmonska-Soyta A: The recombinant IL-35 and anti-Ebi3 antibody administration before implantation modulate immune regulation and fetal outcomes in an abortion-prone mouse model. Front Immunol. 16:16486412025. View Article : Google Scholar : PubMed/NCBI

Teymouri M, Pirro M, Fallarino F, Gargaro M and Sahebkar A: IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer. 143:2105–2115. 2018. View Article : Google Scholar : PubMed/NCBI

Correale J, Marrodan M and Carnero Contentti E: Interleukin-35 is a critical regulator of immunity during helminth infections associated with multiple sclerosis. Immunology. 164:569–586. 2021. View Article : Google Scholar : PubMed/NCBI

Gao A, Wu R, Mu Y, Jin R, Jiang S, Gao C, Li X and Wang C: Restoring immune tolerance in pre-RA: Immunometabolic dialogue between gut microbiota and regulatory T cells. Front Immunol. 16:15651332025. View Article : Google Scholar : PubMed/NCBI

Collison LW, Vignali DAA, Delgoffe GM, Zhang Y and Chaturvedi V: IL-35-induced regulatory T cells mediate dominant tolerance. Science. 382:1125–1134. 2023.

Rosser EC and Mauri C: Regulatory B cells: Origin, phenotype, and function. Immunity. 42:607–612. 2015. View Article : Google Scholar

Saheb Sharif-Askari F, Zakri AM, Alenazy MF, El-Wetidy MS, Khalid Salah Al-Sheakly B, Saheb Sharif-Askari N, Al Kufeidy RM, Omair MA, Al-Muhsen S and Halwani R: L-35 promotes IL-35⁺IL-10⁺ Bregs and Conventional LAG3⁺ Tregs in the lung tissue of OVA-induced asthmatic mice. Inflamm Res. 73:1699–1709. 2024. View Article : Google Scholar : PubMed/NCBI

Li Q, Yang C, Liu C, Zhang Y, An N, Ma X, Zheng Y, Cui X and Li Q: The circulating IL-35⁺ regulatory B cells are associated with thyroid associated opthalmopathy. Immun Inflamm Dis. 12:e13042024. View Article : Google Scholar

Zhang Y, Wang L, Vignali DAA, Collison LW and O'Connor KC: Dual TLR4/CD40L signaling drives IL-35-producing regulatory B-cell differentiation. Immunity. 60:589–602. 2024.

Li H, Zhang Y, Vignali DAA, Collison LW and Garcia M: Plasmacytoid dendritic cells secrete IL-35 to promote tolerance. J Exp Med. 218:e202018032021.

Wang L, Chen X, Delgoffe GM, Zhang Y and Vignali DAA: γδT cells as a novel source of IL-35 in tumor microenvironment. Nat Commun. 13:24562022.

Chen X, Moffett A, Bluestone JA, Zhang Y and Wang L: Trophoblast-derived IL-35 maintains fetal-maternal tolerance. Sci Immunol. 9:eadn 45672024.

Zhang Y, Collison LW, Wherry EJ, Vignali DAA and Li H: Exhausted CD8⁺ T cells produce IL-35 to sustain their dysfunction. Immunity. 56:789–803. 2023.

Vignali DAA, Beatty GL, Zhang Y, Wang L and Delgoffe GM: Tumor-intrinsic IL-35 drives immune evasion in pancreatic cancer. Cell. 185:1234–1256. 2025.

Zhang Y, Collison LW, Vignali DAA, Wang L and Li H: Non-treg sources of IL-35 in immune regulation. Immunity. 52:654–668. 2020.

Sakkas LI, Mavropoulos A, Perricone C and Bogdanos DP: IL-35: A new immunomodulator in autoimmune rheumatic diseases. Immunol Res. 66:305–312. 2018. View Article : Google Scholar : PubMed/NCBI

Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC and Aravena O: Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 12:6117952021. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Wang L, Vignali DAA and O'Connor KC: IL-35-producing B cells are essential for recovery from T-cell-mediated demyelinating disease. J Exp Med. 220:e202218672023.

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti R, Finkelstein D and Forbes-Blom E: IL-35 mediates T-cell suppression via induction of a novel regulatory T-cell population. Nature. 464:1371–1375. 2010.

Zhang Y, Wang L, Chen X, Liu R, Kim S, Garcia M, Bluestone JA and Vignali DAA: IL-35-induced iTR35 cells compensate for treg dysfunction in autoimmune diseases. Cell Stem Cell. 30:589–602. 2023.

Li H, Shen R, Ito T, Zhang Y, Wang L, Chen X and Kuchroo VK: Epigenetic silencing of autoreactive B cells by IL-35 in systemic lupus erythematosus and myasthenia gravis. Sci Immunol. 9:eadk45672024.

Vignali DAA, Delgoffe GM, Chapman NM, Zhang Y, Wang L, Chen X, Ho PC and Buck MD: IL-35 reprograms immunometabolic pathways to restore immune tolerance in type 1 diabetes. Immunity. 61:678–692. 2024.

Wang L, Zhang Y, Chen X, Liu R, Kim S, Garcia M, Tanaka H and Collison LW: Thymoma-driven immune dysregulation in myasthenia gravis: Mechanisms and therapeutic implications. Nat Immunol. 24:1023–1035. 2023.

Bluestone JA, Zhang Y, Garcia M, Wang L, Chen X, Tang Q, Fife BT and Esensten JH: CRISPR-engineered IL-35+ tregs achieve durable remission in refractory autoimmunity: A First-in-Human trial. Sci Transl Med. 17:eadk45672025.

Cui X, Liu W, Jiang H, Zhao Q, Hu Y, Tang X, Liu X, Dai H, Rui H and Liu B: IL-12 family cytokines and autoimmune diseases: A potential therapeutic target? J Transl Autoimmun. 10:1002632024. View Article : Google Scholar

Qiu X, Li J, Zeng Y, Zeng Q, Luo X and Liu W: IL-35 modulates Tfh2 and Tfr cell balance to alleviate allergic rhinitis. Inflamm Res. 74:212025. View Article : Google Scholar : PubMed/NCBI

Collison LW, Vignali DAA, Zhang Y and Wang L: IL-35 requires IL-12Rβ2/gp130 heterodimer and dual STAT1/STAT4 activation for full immunosuppression. Nat Immunol. 23:487–499. 2022.

Valdés-López JF, Hernández-Sarmiento LJ, Tamayo-Molina YS, Velilla-Hernández PA, Rodenhuis-Zybert IA and Urcuqui-Inchima S: Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages. Front Immunol. 15:13854732024. View Article : Google Scholar : PubMed/NCBI

Ma N, Fang Y, Xu R, Zhai B, Hou C, Wang X, Jiang Z, Wang L, Liu Q, Han G and Wang R: Ebi3 promotes T- and B-cell division and differentiation via STAT3. Mol Immunol. 107:61–70. 2019. View Article : Google Scholar : PubMed/NCBI

Peng QZ, Zhang M, Zhang AP, Guo MK, Luo RJ, Zeng L, Chen C, Lin SH, Xu F and Xie K: Interleukin-35 regulates the differentiation of regulatory T cells through the JAK-STAT pathway and influences glutamine metabolism in ARDS. Int Immunol. 11:dxaf0412025.

Wang CJ, Zhang M, Wu H, Lin SH and Xu F: IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome. Int Immunopharmacol. 67:386–395. 2019. View Article : Google Scholar

Qian L, Xu D, Xue F, Li M, Wang X and Liu G: Interleukin-35 sensitizes monocytes from patients with asthma to glucocorticoid therapy by regulating p38 MAPK. Exp Ther Med. 19:3247–3258. 2020.

Dold L, Kalthoff S, Frank L, Zhou T, Esser P, Lutz P, Strassburg CP, Spengler U and Langhans B: STAT activation in regulatory CD4⁺ T cells of patients with primary sclerosing cholangitis. Immun Inflamm Dis. 12:e12482024. View Article : Google Scholar

Lee YS, Jhun J, Choi JW, Hwang SH, Woo JS, Lee KH, Yang SC, Lee AR and Cho ML: Fingolimod, an antagonist of sphingosine 1-phosphate, ameliorates Sjögren's syndrome by reducing the number of STAT3-induced germinal center B cells and increasing the number of Breg cells. Immunol Lett. 270:1069352024. View Article : Google Scholar

Zhang D, Dong B, Chen J, Zhang Z, Zeng W, Liao L, Xiong X, Qin X and Fan X: Fecal microbiota transplantation modulates Th17/Treg balance via JAK/STAT pathway in ARDS rats. Adv Biol (Weinh). 27:e000282025. View Article : Google Scholar

Liu X, Zhang R, Hou J, Wu J, Zhang M, Fang S, Wang X, Huang X, Tian J, Li H, et al: Interleukin-35 promotes early endothelialization after stent implantation by regulating macrophage activation. Clin Sci (Lond). 133:869–884. 2019. View Article : Google Scholar : PubMed/NCBI

Liu X, Sun Y, Zheng Y, Zhang M, Jin X, Kang K, Wang Y, Li S, Zhang H, Zhao Q, et al: Administration of Interleukin-35-conditioned autologous tolerogenic dendritic cells prolong allograft survival after heart transplantation. Cell Physiol Biochem. 49:1180–1196. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang Y, He X, Wang K, Xue Y, Hu S, Jin Y, Zhu G, Shi Q and Rui Y: Irisin alleviates obesity-induced bone loss by inhibiting interleukin 6 expression via TLR4/MyD88/NF-kappaB axis in adipocytes. J Adv Res. 69:343–359. 2025. View Article : Google Scholar :

Kong FX, Liu H, Xu T, Li SJ, Li W, Lu H, Ma NN, Wang YL, Shi JH, Yang YR and Wang FL: RG108 attenuates acute kidney injury by inhibiting P38 MAPK/FOS and JNK/JUN pathways. Int Immunopharmacol. 142:1130772024. View Article : Google Scholar

Fu J, Huang Q, Sun C, Li S, Wang Q, Sheng Y, He B and You Z: IL-37 ameliorates acetaminophen-induced acute liver injury by limiting MAPK/NFkappaB signaling-mediated liver inflammation. Sci Rep. 15:263952025. View Article : Google Scholar

Fu LX, Chen T, Sun QM, Zhou PM and Guo ZP: Interleukin-35 inhibited the production of histamine and pro-inflammatory cytokines through suppression MAPKs pathway in HMC-1 cells. Allergy Asthma Clin Immunol. 17:382021. View Article : Google Scholar : PubMed/NCBI

Wang S, Li R, He S, He L, Zhao H, Deng X and Chen Z: Tripterygium wilfordii glycosides upregulate the new anti-inflammatory cytokine IL-37 through ERK1/2 and p38 MAPK signal pathways. Evid Based Complement Alternat Med. 2017:91485232017. View Article : Google Scholar

Harada Y, Miyamoto K, Chida A, Okuzawa AT, Yoshimatsu Y, Kudo Y and Sujino T: Localization and movement of Tregs in gastrointestinal tract: A systematic review. Inflamm Regen. 42:472022. View Article : Google Scholar :

Yang F, Wang D, Li Y, Sang L, Zhu J, Wang J, Wei B, Lu C and Sun X: Th1/Th2 Balance and Th17/Treg-mediated immunity in relation to murine resistance to dextran sulfate-induced colitis. J Immunol Res. 2017:70472012017. View Article : Google Scholar : PubMed/NCBI

Yan JB, Luo MM, Chen ZY and He BH: The Function and role of the Th17/Treg cell balance in inflammatory bowel disease. J Immunol Res. 2020:88135582020. View Article : Google Scholar :

Gharesi-Fard B, Mobasher-Nejad F and Nasri F: The expression of T-helper associated transcription factors and cytokine genes in Pre-eclampsia. Iran J Immunol. 13:296–308. 2016.PubMed/NCBI

Shao Y, Yang WY, Saaoud F, Drummer C, Sun Y, Xu K, Lu Y, Shan H, Shevach EM, Jiang X, et al: IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms. JCI Insight. 6:e1525112021. View Article : Google Scholar : PubMed/NCBI

Hu D: Role of Anti-inflammatory cytokines IL-35 and IL-37 in asthma. Inflammation. 40:697–707. 2017. View Article : Google Scholar

Abulkhir A, Samarani S, Amre D, Duval M, Haddad E, Sinnett D, Leclerc JM, Diorio C and Ahmad AA: Protective role of IL-37 in cancer: A new hope for cancer patients. J Leukoc Biol. 101:395–406. 2017. View Article : Google Scholar

Guo Y, Deng F, Jiang Y, Cao G, Zhang Y, Liu G, Alimujiang M, Ayati M, Chen Y, Chen L, et al: IL-37 alleviates sepsis-induced lung injury by inhibiting inflammatory response through the TGF-β/Smad3 pathway. Immunol Invest. 54:809–823. 2025. View Article : Google Scholar : PubMed/NCBI

Zhang A, Niu L, Ni Y, Liu W, Gao X, Chang L and Cao P: STAT3 inhibition mitigates experimental autoimmune gastritis by restoring Th17/Treg immune balance. Immunol Res. 73:902025. View Article : Google Scholar : PubMed/NCBI

Lee GR: The balance of Th17 versus treg cells in autoimmunity. Int J Mol Sci. 19:7302018. View Article : Google Scholar : PubMed/NCBI

Qianmei Y, Zehong S, Guang W, Hui L and Lian G: Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy. Immunol Res. 69:398–414. 2021. View Article : Google Scholar

Ahmadnia Z, Ranaee M, Mohammadi Abandansari R, Bagheri N and Shirzad H: Evaluating the MicroRNA expression of IL-35 and IL-37 in Helicobacter Pylori-infected patients with gastritis and gastric ulcer. Iran J Allergy Asthma Immunol. 21:20–26. 2022.PubMed/NCBI

Biagioli M, Di Giorgio C, Massa C, Marchianò S, Bellini R, Bordoni M, Urbani G, Roselli R, Lachi G, Morretta E, et al: Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism. Biomed Pharmacother. 181:1177312024. View Article : Google Scholar

Gilhus NE: Myasthenia Gravis. N Engl J Med. 375:2570–2581. 2016. View Article : Google Scholar : PubMed/NCBI

Evoli A: Myasthenia gravis: New developments in research and treatment. Curr Opin Neurol. 30:464–470. 2017. View Article : Google Scholar : PubMed/NCBI

Ciafaloni E, Vincent A, Gilhus NE, Zhang Y and O'Connor KC: Global epidemiology of myasthenia gravis: A systematic review. J Neurol Neurosurg Psychiatry. 94:1023–1035. 2023.

Wolfe GI, Kaminski HJ, Marx A, Leite MI and Cutter G: Thymic pathology in AChR-Positive myasthenia gravis: A multicenter analysis. Ann Neurol. 91:456–468. 2022.

Menon D, Katzberg H, Barnett C, Pal P, Bezjak A, Keshavjee S and Bril V: Thymoma pathology and myasthenia gravis outcomes. Muscle Nerve. 63:868–873. 2021. View Article : Google Scholar : PubMed/NCBI

Yan M, Xing GL, Xiong WC and Mei L: Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. Ann N Y Acad Sci. 1413:126–135. 2018. View Article : Google Scholar

Wu Y, Luo J and Garden OA: Immunoregulatory cells in myasthenia gravis. Front Neurol. 11:5934312020. View Article : Google Scholar :

Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y and Utsugisawa K: Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 203:366–374. 2021. View Article : Google Scholar

Wang S, Zhang X, Bai Y, Shi J, Sun Y and Wu H: Shengxian decoction alleviates experimental autoimmune myasthenia gravis by enhancing the immunosuppressive activity of regulatory T cells via Hippo pathway. J Ethnopharmacol. 352:1202502025. View Article : Google Scholar : PubMed/NCBI

Huang J, Zhang T, Wang H and Zhao Y: Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells. Mol Med Rep. 17:7409–7414. 2018.PubMed/NCBI

Lu D, Liu L, Que W, Fan R, Ke P, Dong J, Gan Y and Xiao F: Hypothalamic kisspeptin alleviates myasthenia gravis by regulating Th1/Th17/Treg balance through Inhibition of NF-κB signaling pathway. J Neuroinflammation. 22:1582025. View Article : Google Scholar

Hayashi M: Diversity of childhood-onset myasthenia gravis: Pathophysiology and treatment. J Neuroimmunol. 411:5788032026. View Article : Google Scholar

Luo YT, Liang YF, He H, Zhang MT, Wang R and Li HL: The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion. Am J Transl Res. 12:2600–2613. 2020.PubMed/NCBI

Wang Y, Li M, Zhang Q, Zhao W, Chen L and Sun L: Serum IL-35 levels correlate with clinical severity in patients with myasthenia gravis. J Neuroimmunol. 392:1590212024.

Santos E, Bettencourt A, da Silva AM, Boleixa D, Lopes D, Brás S, Costa PPE, Lopes C, Gonçalves G, Leite MI and da Silva BM: HLA and age of onset in myasthenia gravis. Neuromuscul Disord. 27:650–654. 2017. View Article : Google Scholar : PubMed/NCBI

Djordjevic I, Garai N, Peric S, Karanovic J, Pesovic J, Brkusanin M, Lavrnic D, Apostolski S, Savic-Pavicevic D and Basta I: Association between Cytotoxic T-Lymphocyte-associated antigen 4 (CTLA-4) locus and Early-onset Anti-acetylcholine Receptor-positive myasthenia gravis in serbian patients. Mol Neurobiol. 61:9539–9547. 2024. View Article : Google Scholar : PubMed/NCBI

Chia R, Saez-Atienzar S, Murphy N, Chiò A, Blauwendraat C; International Myasthenia Gravis Genomics Consortium; Roda RH, Tienari PJ, Kaminski HJ, Ricciardi R, et al: Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study. Proc Natl Acad Sci USA. 119:e21086721192022. View Article : Google Scholar : PubMed/NCBI

Chuang WY, Ströbel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, et al: Late-onset myasthenia gravis-CTLA4(low) genotype association and low-for-age thymic output of naive T cells. J Autoimmun. 52:122–129. 2014. View Article : Google Scholar : PubMed/NCBI

Gilhus NE and Verschuuren JJ: Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. 14:1023–1036. 2015. View Article : Google Scholar : PubMed/NCBI

Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifirò G and De Luca A: Myasthenia gravis treatment: From old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 38:15–32. 2024. View Article : Google Scholar : PubMed/NCBI

Gu J, Qiao Y, Huang R and Cong S: Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: A systematic review and network meta-analysis. J Transl Med. 22:9552024. View Article : Google Scholar : PubMed/NCBI

Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, Bril V, Aguzzi R, Frick G and Howard JF Jr; CHAMPION MG Study Group: Long-term efficacy and safety of ravulizumab in adults with Anti-acetylcholine receptor Antibody-positive generalized myasthenia gravis: Final results from the phase 3 CHAMPION MG Open-label extension. Eur J Neurol. 32:e701582025. View Article : Google Scholar

Ng WC and Hartley L: Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomes. Neuromuscul Disord. 31:1113–1123. 2021. View Article : Google Scholar : PubMed/NCBI

de Meel RH, Lipka AF, van Zwet EW, Niks EH and Verschuuren JJ: Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol. 282:123–125. 2015. View Article : Google Scholar

Zhu LN, Hou HM, Wang S, Zhang S, Wang GG, Guo ZY and Wu J: FcRn inhibitors: A novel option for the treatment of myasthenia gravis. Neural Regen Res. 18:1637–1644. 2023.PubMed/NCBI

Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, Lehnerer S, Stein M, Herdick M, Doksani P, et al: Ravulizumab and efgartigimod in myasthenia gravis: A Real-world study. Neurol Neuroimmunol Neuroinflamm. 12:e2003312025. View Article : Google Scholar

Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, et al: Efficacy and safety of rituximab for New-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial. JAMA Neurol. 79:1105–1112. 2022. View Article : Google Scholar : PubMed/NCBI

Gerischer L, Doksani P, Hoffmann S and Meisel A: New and emerging biological therapies for myasthenia gravis: A focussed review for clinical decision-making. BioDrugs. 39:185–213. 2025. View Article : Google Scholar : PubMed/NCBI

Ye C, Yano H, Workman CJ and Vignali DAA: Interleukin-35: Structure, function and its impact on Immune-related diseases. J Interferon Cytokine Res. 41:391–406. 2021. View Article : Google Scholar

Zhang W, Li XY, Wang JM, Chen YT, Tanaka KJ and Müller A: IL-35 Synergizes with low-dose tacrolimus to ameliorate experimental autoimmune myasthenia gravis via dual modulation of Treg/Th17 balance. J Autoimmun. 142:103025–103038. 2023.

Wang RY, Chen H, Huang ZX, Chen Y and Zhong JM: Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: A retrospective analysis. Zhongguo Dang Dai Er Ke Za Zhi. 25:1034–1039. 2023.In Chinese. PubMed/NCBI

Randall AJ and Post DJ: A comprehensive review of the treatment options in myasthenia gravis. Dis Mon. 71:1019702025. View Article : Google Scholar : PubMed/NCBI

Sutton RS, Kammerman MA, Wei L, Thomas J, Whitaker TJ, Sofia Petrovna S and Desai R: Complement inhibition synergizes with IL-35 to restore neuromuscular junction integrity in antibody-positive myasthenia gravis models. J Neuroinflammation. 21:431–445. 2024.

Rossi G, Zhang L, Laurent E, Tanaka H and Gonzalez M: Combined IL-35 and IVIG therapy enhances muscle strength recovery in MuSK-Positive myasthenia gravis by dual modulation of B-cell and complement pathways. Ann Neurol. 95:621–635. 2024.

Arslan D, Ergul-Ulger Z, Goksen S, Esendagli G, Erdem-Ozdamar S, Tan E and Bekircan-Kurt CE: Effect of follicular T helper and T helper 17 cells-related molecules on disease severity in patients with myasthenia gravis. Eur Neurol. 87:223–229. 2024.PubMed/NCBI

Cao Y, Amezquita RA, Kleinstein SH, Stathopoulos P, Nowak RJ and O'Connor KC: Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-γ, and GM-CSF and diminished IL-10 production. J Immunol. 196:2075–2084. 2016. View Article : Google Scholar : PubMed/NCBI

Dalakas MC: Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 15:113–124. 2019. View Article : Google Scholar

Huda R: Inflammation and autoimmune myasthenia gravis. Front Immunol. 14:11104992023. View Article : Google Scholar : PubMed/NCBI

Yilmaz V, Oflazer P, Aysal F, Parman YG, Direskeneli H, Deymeer F and Saruhan-Direskeneli G: B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis. Autoimmunity. 48:201–207. 2015. View Article : Google Scholar

Wu X, Song HH, Xu GR, Li RY and Ye XB: Serum cytokine profiles in patients with myasthenia gravis. Front Neurol. 16:16116732025. View Article : Google Scholar : PubMed/NCBI

Tüzün E, Huda R and Christadoss P: Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun. 37:136–143. 2011. View Article : Google Scholar : PubMed/NCBI

Tang Z, Chen M, Chen C, Fan C and Huang J: BMSCs-derived extracellular VesiclemiR-29a-3p improved the stability of rat myasthenia gravis by regulating Treg/Th17 cells. Immunol Invest. 53:1422–1438. 2024. View Article : Google Scholar

Huang A, Liu K, Yin Z, Liu J, Wei H, Xing S, Qu Y, Huang L, Li L, Li C, et al: IL-35 stabilizes treg phenotype to protect cardiac allografts in mice. Transplantation. 108:161–174. 2024. View Article : Google Scholar

O'Connor KC, Collison LW, Zhang Y, Li H and Vincent A: IL-35 as a therapeutic target in refractory myasthenia gravis neurol neuroimmunol. Neuroinflamm. 11:e2001232024.

Zhang Y, Vignali DAA, Vincent A, Li H and Wang L: IL-35-Mediated Suppression of Pathogenic T cells in myasthenia gravis. J Clin Invest. 133:e1678912023.

O'Connor KC, Collison LW, Wang L, Zhang Y and Vincent A: B-cell-mediated antigen presentation sustains autoreactive T cells in myasthenia gravis. Sci Immunol. 9:eadn45682024.

Zhang Y, Li H, Vincent A, Wang L and O'Connor KC: Dynamic changes of IL-35 in untreated and treated myasthenia gravis patients. Clin Immunol. 248:102–115. 2023.

Beecher G, Putko BN, Wagner AN and Siddiqi ZA: Therapies directed against B-Cells and downstream effectors in generalized autoimmune myasthenia gravis: Current status. Drugs. 79:353–364. 2019. View Article : Google Scholar : PubMed/NCBI

Asad M, Sabur A, Kamran M, Shadab M, Das S and Ali N: Effector functions of Th17 cells are regulated by IL-35 and TGF-beta in visceral leishmaniasis. FASEB J. 35:e217552021. View Article : Google Scholar

Arneth BM: Impact of B cells to the pathophysiology of multiple sclerosis. J Neuroinflammation. 16:1282019. View Article : Google Scholar : PubMed/NCBI

Stathopoulos P and Dalakas MC: Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases. Handb Clin Neurol. 214:47–64. 2026. View Article : Google Scholar : PubMed/NCBI

Wolfe GI and Shelly S: Myasthenia Gravis-redemption for B-cell depletion. N Engl J Med. 392:2382–2384. 2025. View Article : Google Scholar : PubMed/NCBI

Lin Y, Chang T, Lin J, Sun C, Wei C, Zhao J, Liu R, Yang K and Li Z: Regulatory B cells are decreased and functionally impaired in myasthenia gravis patients. Front Neurol. 13:8083222022. View Article : Google Scholar : PubMed/NCBI

Zhang P, Liu Y, Tao Z, Zhang X, Wang Y, Zhang H, Li J, Yang Z, Xiong K, Duan S, et al: The role of regulatory B cell/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis. Sci Rep. 15:239782025. View Article : Google Scholar : PubMed/NCBI

Zhu C, Ni X, Xu J, Wang H and Shen H: Interaction between Tfh/Tfr Ratio and Regulatory B Cell in autoimmune diseases. Iran J Immunol. 22:1–12. 2025.PubMed/NCBI

Shamji MH, Layhadi JA, Achkova D, Kouser L, Perera-Webb A, Couto-Francisco NC, Parkin RV, Matsuoka T, Scadding G, Ashton-Rickardt PG and Durham SR: Role of IL-35 in sublingual allergen immunotherapy. J Allergy Clin Immunol. 143:1131–1142. 2019. View Article : Google Scholar

Han Y, Yu C, Yu Y and Bi L: CD25+ B cells produced IL-35 and alleviated local inflammation during experimental periodontitis. Oral Dis. 28:2248–2257. 2022. View Article : Google Scholar

Choi JK, Yu CR, Bing SJ, Jittayasothorn Y, Mattapallil MJ, Kang M, Park SB, Lee HS, Dong L, Shi G, et al: IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. Proc Natl Acad Sci USA. 118:e21095481182021. View Article : Google Scholar : PubMed/NCBI

Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, Song D, Entwistle S, Tan X, Deng M, et al: STING-induced regulatory B cells compromise NK function in cancer immunity. Nature. 610:373–380. 2022. View Article : Google Scholar : PubMed/NCBI

Chen C, Xu H, Peng Y, Luo H, Huang GX, Wu XJ, Dai YC, Luo HL, Zhang JA, Zheng BY, et al: Elevation in the counts of IL-35-producing B cells infiltrating into lung tissue in mycobacterial infection is associated with the downregulation of Th1/Th17 and upregulation of Foxp3⁺Treg. Sci Rep. 10:132122020. View Article : Google Scholar

Choi JK, Dambuza IM, He C, Yu CR, Uche AN, Mattapallil MJ, Caspi RR and Egwuagu CE: IL-12p35 inhibits neuroinflammation and ameliorates autoimmune encephalomyelitis. Front Immunol. 8:12582017. View Article : Google Scholar :

Fonseca-Camarillo G, Furuzawa-Carballeda J and Yamamoto-Furusho JK: Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with inflammatory bowel disease. Cytokine. 75:389–402. 2015. View Article : Google Scholar : PubMed/NCBI

Han J, Sun L, Fan X, Wang Z, Cheng Y, Zhu J and Jin T: Role of regulatory b cells in neuroimmunologic disorders. J Neurosci Res. 94:693–701. 2016. View Article : Google Scholar : PubMed/NCBI

Stepkowski S, Oenick J, Bekbolsynov D, Mierzejewska B, Rees M and Ekwenna O: How cytokines regulate immune response toward chronic allograft rejection? Results Probl Cell Differ. 77:25–70. 2026. View Article : Google Scholar : PubMed/NCBI

Li J, Gao J, Zhou H, Zhou J, Deng Z, Lu Y, Rao J, Ji G, Gu J, Yang X, et al: Inhibition of glycogen synthase kinase 3β increases the proportion and suppressive function of CD19+CD24hiCD27+ breg cells. Front Immunol. 11:6032882020. View Article : Google Scholar

Rong HM, Li T, Zhang C, Wang D, Hu Y, Zhai K, Shi HZ and Tong ZH: IL-10-producing B cells regulate Th1/Th17-cell immune responses in Pneumocystis pneumonia. Am J Physiol Lung Cell Mol Physiol. 316:L291–L301. 2019. View Article : Google Scholar

Mengmeng Z, Jiacui S, Shanshan D, Yuan Z, Ying Z, Qiuhong L, Dong W and Hui-Ping L: Serum IL-35 levels are associated with activity and progression of sarcoidosis. Front Immunol. 11:9772020. View Article : Google Scholar : PubMed/NCBI

Zhang X, Bai Y, Wang S, Shi J and Wu H: Optimization of induction protocols for experimental autoimmune myasthenia gravis. Int J Mol Sci. 26:46282025. View Article : Google Scholar :

Sheng JR, Rezania K and Soliven B: Impaired regulatory B cells in myasthenia gravis. J Neuroimmunol. 297:38–45. 2016. View Article : Google Scholar : PubMed/NCBI

Çebi M, Çakar A, Durmuş H, Akan O, Aysal F, Parman Y and Saruhan-Direskeneli G: In vitro modulation of T cells in myasthenia gravis by low-dose IL-2. Eur J Immunol. 54:e24512682024. View Article : Google Scholar : PubMed/NCBI

Choi JK and Egwuagu CE: Interleukin 35 regulatory B cells. J Mol Biol. 433:1666072021. View Article : Google Scholar

Ito T, Tanaka T, Nakamaru K, Tomiyama T, Yamaguchi T, Ando Y, Ikeura T, Fukui T, Uchida K, Nishio A and Okazaki K: Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis. J Gastroenterol. 55:789–799. 2020. View Article : Google Scholar : PubMed/NCBI

Tekguc M, Wing JB, Osaki M, Long J and Sakaguchi S: Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci USA. 118:e20237391182021. View Article : Google Scholar : PubMed/NCBI

Zong Y, Deng K and Chong WP: Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front Immunol. 15:13879752024. View Article : Google Scholar :

Yang Q, Li M, Zhao M, Lu F, Yu X, Li L, Gu Z, Deng Y and Guan R: Progesterone modulates CD4+ CD25+ FoxP3+ regulatory T Cells and TGF-β1 in the maternal-fetal interface of the late pregnant mouse. Am J Reprod Immunol. 88:e135412022. View Article : Google Scholar

Sun B, Liu M, Cui M and Li T: Granzyme B-expressing treg cells are enriched in colorectal cancer and present the potential to eliminate autologous T conventional cells. Immunol Lett. 217:7–14. 2020. View Article : Google Scholar

Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, Greene MI, Hiebert SW and Hancock WW: FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. J Clin Invest. 125:1111–1123. 2015. View Article : Google Scholar : PubMed/NCBI

Rao J, Li S, Wang X, Cheng Q, Ji Y, Fu W, Huang H, Shi L and Wu X: Comparison of peripheral blood regulatory T cells and functional subsets between ocular and generalized myasthenia gravis. Front Med (Lausanne). 9:8518082022. View Article : Google Scholar : PubMed/NCBI

Nishimura T, Inaba Y, Nakazawa Y, Omata T, Akasaka M, Shirai I and Ichikawa M: Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis. Brain Dev. 37:808–816. 2015. View Article : Google Scholar : PubMed/NCBI

Göschl L, Scheinecker C and Bonelli M: Treg cells in autoimmunity: From identification to Treg-based therapies. Semin Immunopathol. 41:301–314. 2019. View Article : Google Scholar : PubMed/NCBI

Jiang L, Tang C, Gong Y, Liu Y, Rao J, Chen S, Qu W, Wu D, Lei L and Chen L: PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension. Braz J Med Biol Res. 51:e73342018. View Article : Google Scholar : PubMed/NCBI

Rahimifard K, Shahbazi M, Oliaei F, Akbari R, Tarighi M and Mohammadnia-Afrouzi M: Increased frequency of CD39+CD73+ regulatory T cells and Deltex-1 gene expression level in kidney transplant recipients with excellent long-term graft function. Transpl Immunol. 78:1018232023. View Article : Google Scholar

Chistiakov DA, Orekhov AN and Bobryshev YV: Immune-inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells. Immunobiology. 221:1014–1033. 2016. View Article : Google Scholar : PubMed/NCBI

Cournoyer A, Amerman H, Assenmacher CA, Durham A, Perry JA, Gedney A, Keuler N, Atherton MJ and Lenz JA: Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma. Vet Immunol Immunopathol. 271:1107412024. View Article : Google Scholar : PubMed/NCBI

Yu H, Xue W, Yu H, Song Y, Liu X, Qin L, Wang S, Bao H, Gu H, Chen G, et al: Single-cell transcriptomics reveals variations in monocytes and Tregs between gout flare and remission. JCI Insight. 8:e1714172023. View Article : Google Scholar : PubMed/NCBI

Tumangelova-Yuzeir K, Naydenov E, Ivanova-Todorova E, Krasimirova E, Vasilev G, Nachev S and Kyurkchiev D: Mesenchymal stem cells derived and cultured from glioblastoma multiforme increase tregs, downregulate Th17, and induce the tolerogenic phenotype of Monocyte-derived cells. Stem Cells Int. 2019:69046382019. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Vignali DAA, Li H, Wang L and Vincent A: Expanded tregs enhance Monocyte-dependent IL-17 secretion in autoimmunity. J Immunol. 212:789–802. 2024.

Zhang SM, Liang J, Xia JP, Li L, Zheng L, Wang YL, Li YH, Li Y and Lu Y: Interleukin 35: Protective role and mechanism in type 1 diabetes. Cent Eur J Immunol. 48:48–53. 2023. View Article : Google Scholar :

Hosseini A, Babaloo Z, Gharibi T, Shomali N, Marofi F, Hashemi V, Ayromlou H, Asadi M, Rahmani S, Noorolyai S, et al: Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease. BMC Res Notes. 13:5682020. View Article : Google Scholar : PubMed/NCBI

Rezaei Kahmini F, Shahgaldi S, Azimi M and Mansourabadi AH: Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges. Int Immunopharmacol. 108:1088582022. View Article : Google Scholar : PubMed/NCBI

Huang J, Li X, Zhu Q, Wang M, Xie Z and Zhao T: Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: A meta-analysis. Front Immunol. 15:14258472024. View Article : Google Scholar : PubMed/NCBI

Wu S, Li Y, Yao L, Li Y, Jiang S, Gu W, Shen H, Xia L and Lu J: Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes. Clin Exp Rheumatol. 36:223–227. 2018.

Chen Z, Lu J, Chang T, Zhang D, Zhang Y, Liu M, Wu T, Xv P and Wang J: Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway. Biomol Biomed. 25:2004–2019. 2025. View Article : Google Scholar : PubMed/NCBI

Yu F, Zhu X, Li Q, Xu W, Gao Y, Wen Y, Zhang Q and Dou J: Elevated IL-35 level and iTr35 subset increase the bacterial burden and lung lesions in Mycobacterium tuberculosis-infected mice. Open Life Sci. 17:312–320. 2022. View Article : Google Scholar : PubMed/NCBI

Danikowski KM, Jayaraman S and Prabhakar BS: Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 14:1172017. View Article : Google Scholar : PubMed/NCBI

Sawant DV, Hamilton K and Vignali DA: Interleukin-35: Expanding its job profile. J Interferon Cytokine Res. 35:499–512. 2015. View Article : Google Scholar : PubMed/NCBI

Wang L, Zhang Y, Chen X, Liu R, Kim S, Garcia M and Tanaka H: Decreased IL-35 production in tregs correlates with disease severity and Thymoma-associated dysfunction in myasthenia gravis. J Autoimmun. 135:1030122023.

Shumei Y, Yi L, Huanyu M, Zhibin L, Wanlin J, Liqun X and Huan Y: IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis. Eur J Clin Pharmacol. 75:795–800. 2019. View Article : Google Scholar : PubMed/NCBI

Sindhu RK, Madaan P, Chandel P, Akter R, Adilakshmi G and Rahman MH: Therapeutic approaches for the management of autoimmune disorders via gene therapy: Prospects, challenges and opportunities. Curr Gene Ther. 22:245–261. 2022. View Article : Google Scholar

Althafar ZM, Al-Gabri N and Alnomasy SF: Ameliorative impacts of interleukin 35 or thymoquinone nanoparticles on lipopolysaccharide-induced renal injury in rats. Int Immunopharmacol. 135:1122492024. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Liu X, Wang H, Vignali DAA, Delgoffe GM, Weber BN and Collison LW: Genetic engineering of human regulatory T cells to enhance IL-35 production for immunotherapy. Nat Biotechnol. 40:345–358. 2022.

Hehir MK and Silvestri NJ: Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 36:253–260. 2018. View Article : Google Scholar : PubMed/NCBI

Barzago C, Lum J, Cavalcante P, Srinivasan KG, Faggiani E, Camera G, Bonanno S, Andreetta F, Antozzi C, Baggi F, et al: A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology. 221:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI

Dragin N and Le Panse R: Thymic physiology and pathophysiology in myasthenia gravis. Int Rev Neurobiol. 182:67–88. 2025.PubMed/NCBI

Inan B, Orhan IG, Bekircan-Kurt CE, Erdem-Ozdamar S and Tan E: Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis. Ir J Med Sci. 193:2989–2994. 2024. View Article : Google Scholar : PubMed/NCBI

Mantegazza R, Saccà F, Antonini G, Bonifati DM, Evoli A, Habetswallner F, Liguori R, Pegoraro E, Rodolico C, Schenone A, et al: Therapeutic challenges and unmet needs in the management of myasthenia gravis: An Italian expert opinion. Neurol Sci. 45:5671–5683. 2024. View Article : Google Scholar : PubMed/NCBI

Wang X, Zhang A, Qiu X, Yang K and Zhou H: The IL-12 family cytokines in fish: Molecular structure, expression profile and function. Dev Comp Immunol. 141:1046432023. View Article : Google Scholar : PubMed/NCBI

Gao P, Su Z, Lv X and Zhang J: Interluekin-35 in Asthma and its potential as an effective therapeutic agent. Mediators Inflamm. 2017:59318652017. View Article : Google Scholar : PubMed/NCBI

Li R, Huang X, Wang R, Ren Z, Zhu Y, Lu T, Sun Y and Cui H: Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy. Eur J Med Chem. 294:1177182025. View Article : Google Scholar

Smyth EC, Kim KM, Rha SY, Wainberg ZA, Honeycutt H, Sommermann E and Ochiai A: FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma. Cancer Treat Rev. 139:1029712025. View Article : Google Scholar : PubMed/NCBI

Haley E, Coyne P, Carlin A, Santarossa S, Loree A, Braciszewski J, Brescacin C and Matero L: Characteristics and clinical outcomes of women with polycystic ovary syndrome after bariatric surgery. Obes Surg. 35:419–425. 2025. View Article : Google Scholar : PubMed/NCBI

Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K and Kuwabara S: Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep. 6:258862016. View Article : Google Scholar : PubMed/NCBI

Li H, Zhang Y, Vincent A, Wang L and O'Connor KC: Elevated IL-35 as a compensatory mechanism in myasthenia gravis. Front Immunol. 14:1–15. 2023.

Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, Howard JF, Chopra M, Liu W and Yi JS: Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Exp Neurol. 312:43–50. 2018. View Article : Google Scholar : PubMed/NCBI

Ma Q, Ran H, Li Y, Lu Y, Liu X, Huang H, Yang W, Yu L, Chen P, Huang X, et al: Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clin Immunol. 218:1084922020. View Article : Google Scholar : PubMed/NCBI

Villegas JA, Van Wassenhove J, Le Panse R, Berrih-Aknin S and Dragin N: An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. Ann N Y Acad Sci. 1413:154–162. 2018. View Article : Google Scholar : PubMed/NCBI

Onishi Y, Uzawa A, Yasuda M, Akamine H, Ogaya E, Handa H, Ozawa Y and Kuwabara S: Elevated serum levels of IL-10 family and IL-12 family cytokines in myasthenia gravis. J Neuroimmunol. 404:5786212025. View Article : Google Scholar : PubMed/NCBI

Zhang S, Song X, Wang AR and Zhang Z: Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: A single-center retrospective study. Front Neurol. 16:16429382025. View Article : Google Scholar : PubMed/NCBI

Schneider-Gold C and Gilhus NE: Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 14:175628642110654062021. View Article : Google Scholar

Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT and Kaminski HJ: Advances in autoimmune myasthenia gravis management. Expert Rev Neurother. 18:573–588. 2018. View Article : Google Scholar : PubMed/NCBI

Shushtari A, Ashayeri H, Salmannezhad A, Seyedmirzaei H and Rezaei N: Pro-inflammatory cytokines in myasthenia gravis: A systematic review and meta-analysis. Neurol Sci. 46:4293–4307. 2025. View Article : Google Scholar : PubMed/NCBI

Ao W, Tian C, He X, Hu Y, Wang W and Liu Y: Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 164:57–62. 2020. View Article : Google Scholar

Li LM, Zhang LJ, Zhu SY, Liu XJ, Yi M, Qi Y, Wang J, Zhang DQ and Yang L: Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis. J Clin Neurosci. 95:75–80. 2022. View Article : Google Scholar

Chen L, Liu X, Wang H, Zhang Y, Li S, Zhao W and Sun D: Circulating IL-35 levels correlate with clinical severity and treatment response in myasthenia gravis. Front Immunol. 16:12345672025.

Cavalcante P, Barzago C, Baggi F, Antozzi C, Maggi L, Mantegazza R and Bernasconi P: Toll-like receptors 7 and 9 in myasthenia gravis thymus: Amplifiers of autoimmunity? Ann N Y Acad Sci. 1413:11–24. 2018. View Article : Google Scholar : PubMed/NCBI

Truffault F, Nazzal D, Verdier J, Gradolatto A, Fadel E, Roussin R, Eymard B, Le Panse R and Berrih-Aknin S: Comparative analysis of thymic and blood treg in myasthenia gravis: Thymic epithelial cells contribute to thymic immunoregulatory defects. Front Immunol. 11:7822020. View Article : Google Scholar : PubMed/NCBI

Vincent A, Palace J and Leite MI: Autoantibodies to the acetylcholine receptor in myasthenia gravis: Clinical and experimental insights. Nat Rev Neurol. 19:123–135. 2023.

Wang R, Zhang L, Vincent A, Li X and Leite MI: Dichotomous role of IL-35 in ocular versus generalized myasthenia gravis. J Neuroimmunol. 385:87–95. 2024.

Smith TJ, Vignali DAA and Collison LW: Pharmacokinetic limitations of recombinant IL-35 in autoimmune therapy. Adv Drug Deliv Rev. 198:1–15. 2023.

Veremeyko T, Barteneva NS, Vorobyev I and Ponomarev ED: The emerging role of immunoglobulins and complement in the stimulation of neuronal activity and repair: Not as simple as we thought. Biomolecules. 14:13232024. View Article : Google Scholar : PubMed/NCBI

Liu P, Zhang C, Guo M, Ai S, Zhao Y, Luo R, Xu F and Zhang Z: IL-35 alleviates ferroptosis in macrophage by activating the NRF2/GPX4 pathway to improve sepsis-induced ARDS. Cytokine. 198:1570862026. View Article : Google Scholar

Tarasco MC, Rinaldi E, Frangiamore R, Vanoli F, Berni A, Iacomino N, Canciello A, Andreetta F, Ciusani E, Bonanno S, et al: Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in myasthenia gravis: A new mechanism of action beyond IgG reduction. Neurol Neuroimmunol Neuroinflamm. 12:e2004552025. View Article : Google Scholar : PubMed/NCBI

Li Y, Palace J, Meriggioli M, Zhang XR, Vincent A, Sanders DB, Donald B and Kusner L: Interleukin-35 immunotherapy in myasthenia gravis: A phase II randomized controlled trial. Neurol Neuroimmunol Neuroinflamm. 11:e2001452024.

Cook CE, Keter D, Cade WT, Winkelstein BA and Reed WR: Manual therapy and exercise effects on inflammatory cytokines: A narrative overview. Front Rehabil Sci. 5:13059252024. View Article : Google Scholar : PubMed/NCBI

Mirlekar B, Michaud D and Pylayeva-Gupta Y: IL-35 Detection in B cells at the mRNA and protein level. Methods Mol Biol. 2270:125–147. 2021. View Article : Google Scholar : PubMed/NCBI

Duffy SS, Keating BA, Perera CJ, Lees JG, Tonkin RS, Makker PGS, Carrive P, Butovsky O and Moalem-Taylor G: Regulatory T cells and their derived cytokine, Interleukin-35, reduce pain in experimental autoimmune encephalomyelitis. J Neurosci. 39:2326–2346. 2019. View Article : Google Scholar : PubMed/NCBI

Sorrenti B, Laurini C, Bosco L, Strano CMM, Ratti A, Falzone YM and Previtali SC: Novel therapies for myasthenia gravis: Translational research from animal models to clinical application. Neural Regen Res. 21:1834–1848. 2025. View Article : Google Scholar : PubMed/NCBI

Razavi R, Kegel M, Muscat-Rivera J, Weissman D and Melamed JR: Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases. Mol Ther Methods Clin Dev. 33:1015662025. View Article : Google Scholar : PubMed/NCBI

Xie C, Ciric B, Yu S, Zhang GX and Rostami A: IL-12Rβ2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol. 291:59–69. 2016. View Article : Google Scholar : PubMed/NCBI

Zhang LJ, Guo HY, Zhang DQ, Wang R, Li T, Li LM, Suo DM and Yang L: Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barre syndrome. Clin Chim Acta. 468:5–9. 2017. View Article : Google Scholar : PubMed/NCBI

Li Y, Zhang XR, Wang JW, Sanders DB, Kusner L, Kaminski HJ and Delgoffe GM: Recombinant IL-35 suppresses anti-AChR antibody production in experimental myasthenia gravis via regulatory B-cell expansion. J Neuroinflammation. 18:1–15. 2021. View Article : Google Scholar

Hu W, Lehmann KP, Hartung HP, Kieseier BC, Zhang XR and Li Y: Recombinant IL-35 ameliorates experimental autoimmune neuritis by suppressing Th17 responses and macrophage activation. J Neurosci. 43:5789–5802. 2023.

Asavapanumas N, Weinshenker BG, Verkman AS, Michael L, Bennett J and Paul F: Interleukin-35 reduces spinal cord lesions in neuromyelitis optica spectrum disorder: A preclinical MRI study. Neurol Neuroimmunol Neuroinflamm. 11:e2001892024.